News and trends on diagnostics testing, insurance coverage, and reimbursement.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Starting Oct. 1, the insurer will require clinicians and labs who order genetic and molecular tests for their patients to first get approval.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
